Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease

BACKGROUND: There are phase 3 clinical trials underway evaluating anti-PD-L1 antibodies as adjuvant (postoperative) monotherapies for resectable renal cell carcinoma (RCC) and triple-negative breast cancer (TNBC); in combination with antiangiogenic VEGF/VEGFR2 inhibitors (e.g., bevacizumab and sunit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Florence T. H., Xu, Ping, Chow, Annabelle, Man, Shan, Krüger, Janna, Khan, Kabir A., Paez-Ribes, Marta, Pham, Elizabeth, Kerbel, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342972/
https://www.ncbi.nlm.nih.gov/pubmed/30498230
http://dx.doi.org/10.1038/s41416-018-0297-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342972/
https://www.ncbi.nlm.nih.gov/pubmed/30498230
http://dx.doi.org/10.1038/s41416-018-0297-1

Ejemplares similares